The largest database of trusted experimental protocols

12 protocols using prostar 325

1

HPLC Analysis of Compounds of Interest

Check if the same lab product or an alternative is used in the 5 most similar protocols
A total ion chromatogram (TIC) was obtained using an Agilent Varian ProStar HPLC system equipped with a ProStar 325 UV-Vis detector (ProStar 325, Varian, Palo Alto, USA) and a C18 column (Pursuit, Agilent Technologies, Inc., Santa Clara, CA, USA), which was protected with a guard column. For the mobile phase, pump A utilized Milli-Q water (Millipore-Merck, Darmstadt, Germany) acidified with 0.1% acetic acid; Pump C used HPLC-grade acetonitrile (Merck, Darmstadt, Germany) and pump B used methanol (HPLC grade, Merck, Darmstadt, Germany) to clean the column. The program used for elution was carried out from 0 to 15 min with gradient ranged from 95% A and 0.5% C to 72% A and 28% C. Then the gradient ranged from 72% A and 28% C to 32% A to 68% C in the interval between 16 and 55 min, reaching the concentration of 100% for C in the interval of 55–60 min. The detection of compounds of interest was performed at a wavelength (λ) of 254 nm, and the volume injected was 20 μl, with the mobile phase flow set at 0.6 ml/min.
+ Open protocol
+ Expand
2

Synthesis and Purification of Glucuronides

Check if the same lab product or an alternative is used in the 5 most similar protocols
The four glucuronides (Figure 1) were obtained by hemisynthesis as previously described [50 (link)] with some modifications. One molar equivalent εVin was dissolved in ethanol and then mixed with 20 molar equivalents of K2CO3. Six molar equivalents of acetobromo-glucuronic acid methyl-ester dissolved in ethanol were added, and the reaction mixture was stirred at 50 °C for 24 h under agitation. The reaction was then stopped by lowering the pH below 5 with 1% formic acid. Solvents were evaporated with a vacuum rotatory evaporator before redissolving sample in methanol:water (50:50, v:v). The mixture was injected into semi-preparative high-performance liquid chromatography equipped with a binary pump and UV-VIS detector used at 320 nm (Prostar 325, Varian, Palo Alto, CA, USA). Solvents A and B were ultra-pure water and acetonitrile:water (50:50, v:v), respectively, both acidified with 0.025% of TFA. The gradient, used with a 2 mL/min flow rate, was as follows: 0 min, 38% B; 0–55 min, 38–48% B; 55–57 min, 48–100% B; 57–60 min, 100% B; 60–62 min, 100–38% B; 62–64 min; 38% B. Metabolites were individually collected and then injected in UPLC-DAD-MS to ensure their purity before being freeze-dried. For method validation and a calibration curve, V2G (Figure 1) was used as it is the most predominant isomer found in rats [33 (link)].
+ Open protocol
+ Expand
3

Synthesis and Purification of miRNA Mimics

Check if the same lab product or an alternative is used in the 5 most similar protocols
The unmodified RNA oligomers were synthesized in Division of Bioorganic Chemistry of CMMS PAS Łódź by dr Anna Maciaszek using Gene World automated DNA/RNA synthesizer at a 0.2 μmol scale, with commercially available LCA–CPG supports (Biosearch Technologies, Inc., Petaluma, CA) and the standard phosphoramidite monomers (Glen Research, Sterling, VA, USA). The phosphoramidites were dissolved in anhydrous CH3CN at concentration of 0.07 M, and a 0.25 M solution of 5-Benzylmercapto-1H-tetrazole in anhydrous CH3CN was used as an activator. Oligonucleotides were deprotected and isolated using a binary Varian HPLC system, consisting of two PrepStar 218 pumps and a ProStar 325 UV/VIS detector set at 260 nm. A reverse phase HPLC column (PRP-1, C18, 7 μm, 305 × 7 mm, Hamilton, Reno, NV, USA) was eluted with a 1% min − 1 gradient of CH3CN in 0.1 M TEAB (pH 7.3) at a flow rate 2.5 ml min − 1. The miR494 and miR146a mimics sequences: miR494-5p 5ʹ-AGGUUGUCCGUGUUGUCUUCUC-3ʹ; miR494-3p 5ʹ-UGAAACAUACACGGGAAACCUC-3ʹ; miR146a-5p 5ʹ-UGAGAACUGAAUUCCAUGGGUU-3ʹ; miR146a-3p 5ʹ-CCUCUGAAAUUCAGUUCUUCAG-3’.
+ Open protocol
+ Expand
4

Comprehensive Physicochemical Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols
Optical rotations were measured on a PerkinElmer 241 polarimeter in a 100 × 2 mm cell. UV and IR spectRa were obtained using a Varian Cary 50 Bio UV–visible spectRophotometer and a PerkinElmer SpectRum 2000 FT-IR spectRometer, respectively. 1H, 13C, COSY, HSQC, HMBC, and ROESY experiments were performed in MeOH-d4 and acetone-d6 using a Bruker Avance III spectRometer operating at 600 MHz for 1H and 150 MHz for 13C and equipped with a 3 mm cryogenically cooled probe. SpectRa were calibrated to residual solvent signals at δH 3.31 and δC 49.0 (MeOH-d4). HPLC was performed using a Varian ProStar 218 solvent delivery module HPLC equipped with a Varian ProStar 325 UV–vis detector, operating under Star 6.41 chromatography workstation software. ESIMS studies were carried out on an Agilent 6130 Quadrapole LC/MS system.
+ Open protocol
+ Expand
5

HILIC Purification of Oligomeric Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
Purification was performed on a Luna HILIC column (21.2 × 250 mm, 5 μm, Phenomenex) by a Varian LC machine consisting of a Prostar 210 two-way binary high-pressure gradient pump, a 2 mL loop and a Prostar 325 UV/Visible detector. Chromatographic peaks were manually collected. The mobile phase consisted of acidified acetonitrile (Eluent A) and acidified aqueous methanol (Eluent B. Methanol: water. 95:5. v/v), both containing 0.025% trifluoroacetic acid. The flow rate was 22 mL/min and eluent B followed this gradient: 0 min, 7%; 57 min, 37.6%; 60 min, 100%; 67 min, 100%; 73 min, 7%; 83 min, 7%, 52 min. For each injection, 100 mg of fraction compounds were dissolved in 0.5 mL methanol and manually injected into the system. UV detection was carried out at 254 nm and 280 nm. After successive injections, the purified oligomers were evaporated in vacuo to remove solvent and freeze-dried to obtain the targeted monomers, dimers, trimers, tetramers and pentamers in powder.
+ Open protocol
+ Expand
6

Hemi-Synthesis Metabolite Separation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Samples from chemical hemi-synthesis were separated by HPLC equipped with a binary pump, an UV-VIS detector (Prostar 325, Varian, Palo Alto, CA, USA), and Prontosil C18 column (5 µm, 8 × 250 mm). Detection was carried out at 320 nm.
Solvents and the gradient employed for the separation of ε-viniferin metabolites were as follows: solvent A (H2O 0.025% TFA); solvent B (acetonitrile 0.025% TFA); gradient program 0–4 min, 10% B; 4–9 min, 10–20% B; 9–13 min, 20–30% B; 13–17 min, 30% B; 17–21 min, 30–35%; 21–30 min, 35–60%; 30–38 min, 60–100%; 38–44 min, 100% (Figure S1, Supplementary Materials). The flow rate was set to 3 mL/min. Peaks were collected, concentrated under vacuum, and freeze-dried. The metabolites were identified by HPLC-DAD-MS and NMR analysis.
+ Open protocol
+ Expand
7

Quantifying Drug Release from Polymer Films

Check if the same lab product or an alternative is used in the 5 most similar protocols
The drug-loaded films (2 cm × 2 cm) were cut into small pieces and were placed into 20 mL phosphate buffer saline (pH = 6.8). Then the samples were stirred on a magnetic stirrer, sonicated for 5 min, and filtered using Chromafil® syringe filter (0.45 μm). The amount of model drugs was determined using HPLC chromatographic system Varian ProStar 325 (Palo Alto, CA, USA) with PDA 335 detector, and Hypersil GOLD C18 column (150 × 4.6 mm, 5 μm) (Thermo Fisher Scientific, Pittsburgh, PA, USA) under the conditions presented in Table 1. The pump supplied a 1 mL/min flow rate of the mobile phase. The chromatograms were recorded for 6 min at 25 °C, and the retention time is shown in Table 1. The drug concentration was calculated from a standard calibration curve of the drugs in mobile phase using Star Chromatography Workstation software (version 6.30). Mean results of triplicate measurements and standard deviation were reported.
+ Open protocol
+ Expand
8

HPLC Analysis of Bioactive Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
HPLC analysis was performed as described by Kerkhoff et al. (2016) (link). Briefly, chromatography analysis was executed on a HPLC system LC Varian Pro Star 325 with ultraviolet detector Pro Star 325 with dual wavelength system, the equipment was operated by Galaxie Chromatogrphy Date System Software, provided by the equipment manufacturer. The separation was performed on Phenomenex Luna C18 (250.0 × 4.6 mm, 5 μm). Samples were eluted to mobile phase with water (eluent A) and acetonitrile (eluent B). Elution took place according to gradient and mobile phase flow as it follows: 0–45 min with 0–70% solvent B; flow: 0,80 mL/min. The injection volume was 20 μL and detection at 296 nm. The identification of the compounds was made by comparing the retention time (RT) of the peaks with the standards of the pure compounds (Resinobufagin, Marinobufagin and Bufalin), the standards were injected separately to obtain the RT of each compound. The other peaks were not identified by HPLC-UV due to lack of standards. However, in a previous work, the methanolic extract from RmP was analyzed by UHPLC-DAD-MicOTOF-MS-MS and twelve compounds were identified (Pelissari et al., 2021 ).
+ Open protocol
+ Expand
9

Lactoferrin Quantification by RP-HPLC

Check if the same lab product or an alternative is used in the 5 most similar protocols
In order to evaluate the content of lactoferrin, RP-HPLC method was used. All samples were prepared according to Brodziak et al. [27 (link)] with a modification (5 mL of yoghurt instead of milk). Protein analysis was performed on liquid chromatograph ProStar 210 model and UV-VIS ProStar 325 detector (Varian, Palo Alto, CA, USA). The measurements were carried out using the water/acetonitrile mobile phase at gradient elution and column Nucleosil 300-5 C18 (Varian, Palo Alto, CA, USA) of 250 mm length and 4.6 mm diameter. The mobile phase was solvent A (90% water, 10% acetonitryle) and solvent B (90% acetonitryle, 10% water), purchased from Sigma-Aldrich (St. Louis, MO, USA). The analysis time for a single sample was 15 min at 205 nm wavelength with column temperature of 37 °C. The analysis of reference substance—commercially available lactoferrin (purity—90%, Sigma-Aldrich (St. Louis, MO, USA)), was conducted under the same conditions. On the grounds of the obtained chromatograms, the qualitative and quantitative identification of LF was performed.
+ Open protocol
+ Expand
10

Liposomal Encapsulation of Hydrophobic Drug ESC8

Check if the same lab product or an alternative is used in the 5 most similar protocols
Liposomes were prepared according to previous protocol.31 (link) The final molar ratios of the component in the DO liposome was 1:1, DODEAC/Chol; while in the DX liposome was 1:1:0.75, DODEAC/Chol/Dex. For the preparation of liposome containing hydrophobic ESC8 drug, ESC8 was added to the lipid mixture of DO or DX at 0.25 molar ratio to get the liposome DOE (DO/ESC8, 1:0.25 molar ratio) or DXE (DX/ESC8, 1:0.25 molar ratio). One millimolar liposome (with respect to cationic lipid) was used for all in vitro studies. For animal studies, 5 mM liposome (with respect to cationic lipid) was used and was dispersed in 5% glucose solution. To determine the encapsulation efficiency, ESC8-loaded liposome was centrifuged for 45 min at 5000 rpm to remove nontrapped ESC8, and then 200 μL of liposome was lysed by mixing with 800 μL of methanol. The solution was then passed through a 0.22 μm filter and analyzed by reversed phase-HPLC method with a UV detector (Varian Prostar 325, at a wavelength of 210 nm) using methanol–acetonitrile (80:20, v/v) as mobile phase. The drug encapsulation efficiency (EE%) was calculated using below formula:
encapsulationefficiency(%)=(wtofliposomallyentrappeddrug/wtoftotaldrugused)×100
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!